June 10, 2015
This video from the National Institute of Allergy and Infectious Diseases (NIAID) looks at current efforts to improve hepatitis C (HCV) treatment, including curing hard-to-treat HCV, particularly in patients who are coinfected with HCV and HIV. In the District of Columbia, where an estimated 15,000 people are living with HCV, researchers and patients discuss the difficulties of managing and treating HCV.
Many hepatitis C patients do not complete the standard treatments because these therapies are complex, lengthy and can cause severe side effects, according to the video. "If you don't do anything, a lot of these patients will develop liver failure and die," says Shyamasundaran Kottilil, M.D., Ph.D., in an on-screen interview.
However, the video highlights the high cure rates of available HCV drugs, as well as current clinical trials focusing on newer treatments with shorter duration and fewer side effects. Study participants in these trials also receive other care, including support to quit drinking and using other drugs.
Watch the video:
Warren Tong is the senior science editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
Copyright © 2015 Remedy Health Media, LLC. All rights reserved.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Sex and the HIV Reservoir: New Research Points to the Powerful Effect of Estrogen|
|First U.S. Failure of Truvada as PrEP Is Reported at IDWeek|
|Post-AIDS 2018 Updates on HIV Cure Research|
|On-Demand PrEP Is Great. Now, What About Women?|
|High Rates of Anal HPV Infection in Gay Men Using PrEP in IPERGAY: The Role of Vaccination|